Relapsed or Refractory Acute Myeloid Leukemia (AML) clinical trials

CAR-T Cell Therapy for Standard-Risk B-ALL After Chemotherapy

This trial tests a new type of immunotherapy called CAR-T cells to help prevent relapse in adults with B-cell acute lymphoblastic leukemia (a blood cancer) who have responded well to standard chemotherapy. The treatment is designed as a consolidation therapy to strengthen remission after initial chemotherapy.

Natural killer cells for hard-to-treat neuroblastoma

This trial tests specially prepared immune cells (called CIML-NK cells) from a partially matched family donor to fight neuroblastoma that has returned or stopped responding to standard treatment. The goal is to see if these cells can help patients whose cancer is difficult to control.

CAR-T cell therapy for active autoimmune disease flare-ups

This study tests an immune-cell treatment (CAR-T, called BRL-301) in people with certain autoimmune diseases that are active and hard to control. It may help your immune system calm down if standard treatments have not worked or your disease has returned.

Ruxolitinib for relapsed or hard-to-treat T/NK cell lymphoma

This trial studies ruxolitinib, a medicine that affects immune signaling, in people whose T-cell or NK-cell lymphoma has returned or hasn’t responded to treatment. It may help shrink lymphoma and improve symptoms after other therapies.

Onivyde plus talazoparib or temozolomide for resistant solid tumors

This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.

Tegavivint for kids and young adults with hard-to-treat solid tumors

This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.

BCMA gene therapy for recurring autoimmune diseases

This early-phase trial tests a new gene therapy (BCMA LV injection) for people with autoimmune diseases like lupus, IgG4-related disease, scleroderma, myositis, or vasculitis that keep coming back or don't respond to standard treatments. The goal is to see if targeting a specific immune cell protein (BCMA) can help control the disease.

Study drug IACS-6274 tested for advanced solid tumors

This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.

Epcoritamab with chemo before stem cell transplant for DLBCL

This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.

Registry study for chronic lymphocytic leukemia patients

This study is a registry that collects information about people with certain types of leukemia. It may help researchers understand the disease course and how patients are treated, including people who are newly diagnosed, currently treated, referred for transplant, or have relapsed.

New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT

This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.

Selinexor plus low-dose steroid for hard-to-treat myeloma

This Phase 2 trial tests selinexor (a targeted anti-cancer medicine) plus low-dose dexamethasone to treat multiple myeloma that has not responded to many prior treatments. It compares selinexor combinations depending on what medicines you’ve already had, aiming to reduce myeloma activity and improve outcomes.

Checking treatment for multiple myeloma after MRD becomes negative

This study looks at whether people with newly diagnosed multiple myeloma can safely continue or adjust treatment after they reach “MRD-negative,” meaning very low signs of disease in the bone marrow. It may help reduce the chance of relapse while avoiding unnecessary treatment for some patients.

Therapy program to reduce drinking relapse and PTSD symptoms

This Phase 2 study tests a combined therapy approach for people who have both alcohol use disorder and post-traumatic stress disorder (PTSD). It aims to help you process stressful memories and lower the chances of relapse back to heavy drinking.

Study of body markers in recurrent glioblastoma

This study looks at special markers in the blood and tumors of people whose glioblastoma has come back. It may help doctors understand why the cancer returns and how to treat it better.

Viral therapy for peripheral T-cell lymphoma

This study tests an experimental virus therapy given through a vein for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The virus is designed to infect and destroy cancer cells. Some patients may also receive another drug called cemiplimab as part of a combination group.

Thalidomide for symptomatic large granular lymphocytic leukemia

This trial tests the drug thalidomide for people with symptomatic large granular lymphocytic leukemia (LGLL), a rare blood cancer. It aims to see if thalidomide can help control the disease and improve symptoms like low blood counts or an enlarged spleen.

Rituximab and Zanubrutinib for hairy cell leukemia

This trial tests a combination of two targeted drugs, rituximab and zanubrutinib, for people with hairy cell leukemia or its variant. It aims to see if this therapy works for those who have already had one type of chemotherapy or who cannot take a standard treatment called purine analogs.

Cladribine plus rituximab for hairy cell leukemia

This trial tests whether a combination of two medicines—cladribine and rituximab—can treat hairy cell leukemia. You might be able to join if your leukemia is confirmed and you meet timing, blood test, and health requirements.

Nemtabrutinib plus venetoclax versus standard add-on therapy

This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.

A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis

Switching to remibrutinib from ocrelizumab for relapsing MS

This study tests a new oral medication called remibrutinib for people with relapsing MS who are currently on ocrelizumab. The goal is to see if switching to remibrutinib is safe and effective for controlling MS long-term.

Mindfulness training to prevent relapse for peer support workers

This study tests a mindfulness-based program to help people who work as peer support specialists in substance use recovery reduce their risk of relapse. It may help you manage cravings and stay healthy in your role.

Comparing two drugs for CLL or SLL after prior treatment

This trial tests a new drug (BGB-16673) against another drug (pirtobrutinib) for people with CLL or SLL that hasn't responded to or has come back after a prior BTK inhibitor treatment. The goal is to see which drug is more effective and safe.